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Abstract
MicroRNAs are emerging as new mediators in the regulation of adipose tissue biology and the development of obesity. An
important role of microRNA-125a has been suggested in the pathogenesis of insulin resistance (IR). Here, we characterized
the function of microRNA-125a in adipose tissue in a context of experimentally-induced IR and obesity in mice and in obese
patients. We showed time dependent overexpression of the microRNA in adipose tissue of BALB/c and C57BL/6J mice in
response to high fat diet (HFD) feeding. MicroRNA-125a expression was downregulated in vitro in insulin resistant 3T3-L1
adipocytes and ex vivo in adipose tissue of obese patients. In vitro modulation of microRNA-125a expression in 3T3-L1
adipocytes did not affect glucose uptake. Gene set enrichment analysis (GSEA) identified significantly altered expression
patterns of predicted microRNA-125a gene targets in transcriptomic datasets of adipose tissue from HFD-fed mice and
obese patients. Among genes that contributed to global enrichment of altered expression of microRNA-125a targets,
Thyrotroph embryonic factor (Tef ), Mannan-binding lectin serine peptidase 1, Reticulon 2 and Ubiquitin-conjugating
enzyme E2L3 were significantly differentially expressed in adipose tissue in these groups. We showed that Tef expression is
reduced in adipose tissue of obese patients following gastric bypass surgery. Our findings indicate that microRNA-125a
expression in adipose tissue adapts to IR and may play a role in the development of obesity in mice and obese subjects
through uncoupled regulation of the expression of microRNA-125a and its targets.
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Introduction
Obesity and type 2 diabetes mellitus (T2DM) are major health
issues caused by a complex interplay between genetic risk factors
and environmental influences, including sedentary lifestyle and
change in feeding behavior [1,2]. Insulin resistance (IR) is a
cardinal pathophysiological feature in these chronic diseases [3].
Defining molecular signatures of the onset and progression of
T2DM and obesity has become crucial to provide a deeper
understanding of the mechanisms involved and uncover predictive
and therapeutical targets. Owing to the complexity of molecular
studies in humans and limitations in access to organ biopsies in
patients and controls, animal models of obesity and T2DM
represent powerful tools to identify etiological mechanisms of IR.
Models of spontaneously-occurring T2DM, such as the Goto
Kakizaki (GK) rat [4], and experimentally-induced obesity by high
fat diet (HFD) feeding [5] are widely used to identify novel genes
and gene pathways involved in IR. We have previously
demonstrated contrasting pathophysiological responses to HFD
in C57BL/6J and BALB/c mice [6,7].
Progress in molecular genetic technologies, which allows deeper
analyses of genome expression patterns contributing to, or reactive
to, a disease phenotype, has underlined new molecular mecha-
nisms mediated by microRNAs (miRs) in the biology of adipose
tissue and the development of obesity [8,9,10,11]. MiR is a family
of highly conserved, single-stranded, 19–23 nucleotide long, non-
coding, endogenous RNAs, which negatively regulate gene
expression either by inhibiting translation or by degrading target
mRNAs [12]. One miR can target several mRNAs and one
transcript can be targeted by several miRs. Such interactions
regulate various aspects of metabolism through pancreatic
development, insulin biosynthesis, secretion and signaling, adipo-
cyte differentiation and glucose uptake [8,13].
We have demonstrated differential expression of a series of
miRs in the GK rat model of polygenic IR [14,15]. Consistent
overexpression of miR-125a in both liver and adipose tissue of the
GK rat suggested that this miR may play an important role in IR
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pathogenesis [14]. To further characterize its function in a context
of experimentally-induced IR, we investigated the regulation of the
expression of this miR and its proposed transcript targets in
adipose tissue from C57BL/6J and BALB/c mice fed HFD and
from obese patients. Our results indicate that miR-125a expression
is reactive to IR and suggest that uncoupled differential expression
of miR-125a and its mRNA targets may play a role in the
development of obesity.
Methods
Patients
Seventeen severely obese patients, who were candidates for
bariatric surgery and 7 non-obese subjects were included in a study
protocol approved by the Ethics Committee of Hotel-Dieu
Hospital, and signed informed written consent. Physiological
parameters are listed in Table 1. In the group of 17 severely obese
patients, 7 patients had T2DM. Body mass index was calculated
from the measured body weight and height. Subcutaneous
periumbilical adipose and omental biopsies were collected at the
time of surgery. Blood samples were obtained at each time point
after 12 h overnight fasting and stored at 220uC until assays of
plasma total cholesterol, triglycerides, insulin, glucose, leptin,
adiponectin, and liver marker, c-glutamyltransferase (cGT).
Pangenomic expression of subcutaneous adipose tissue was
conducted before and after gastric surgery as described [16]. Fat
and fat-free mass were determined by dual-energy X-ray
absorptiometry (GE Lunar Prodigy Corp., Madison, WI).
QUICKI was determined by a mathematical calculation using
fasting glucose and insulin as described previously by Katz et al.
[17]. These evaluations were performed before surgery and during
the post-surgery follow-up. Plasma glucose, triglycerides, and total
cholesterol levels were measured enzymatically. Serum insulin
concentrations were determined with immunoradiometric assay
(Bi-INSULIN IRMA CisBio International, Gif-sur-Yvette,
France). Serum leptin and adiponectin were determined using
radioimmunoassay kits (Linco Research, Saint Louis, MI, USA).
Animals
Male C57BL/6J and BALB/c mice were bred from Jackson
laboratory stocks. Mice were weaned at 3 weeks and fed a control
carbohydrate diet (CHD) containing 5% fat, 19% protein and
3.5% fibers (S&K Universal Ltd, Hull, United Kingdom). At 5
weeks, a group of mice was transferred to 40% HFD (High-fat
diet) containing 40% saturated fat, 19% protein, 21% glucose
(Special Diet Services, Witham, United Kingdom) ad libitum,
whereas the control group remained on CHD. Mice fed HFD for
1 week and 15 weeks, and age-matched controls were killed by
CO2 asphyxiation. Epididymal fat pads (EPD) were rapidly
dissected and snap frozen in liquid nitrogen and then stored at
280uC. Animal procedures were carried out under United
Kingdom Home Office personal and project licences and
approved by the ethical review panel of the University of Oxford.
Glucose tolerance and insulin secretion tests in mice
Intraperitoneal glucose tolerance tests were performed in
overnight fasted mice. Briefly, mice were anesthetized with an
intraperitoneal injection of sodium pentobarbital (Sagatal, Rhoˆne
Me´rieux, Harlow, United Kingdom) and a solution of glucose
(2 g/kg body weight) was injected intraperitoneally. Blood samples
were collected from the tail vein before the injection and 15, 30
and 75 min afterward. Blood glucose was immediately determined
with a glucose meter (Accucheck, Roche Diagnostics, Burgess Hill,
United Kingdom). Plasma samples were stored at 280uC until
assayed for immunoreactive insulin (ELISA, Mercodia, Uppsala,
Sweden). Cumulative glycemia and insulinemia were calculated as
the increment of the values of plasma glucose and insulin,
respectively, during the test. Characterization of the short and
long-term consequences of fat feeding on the onset and
progression of insulin resistance, diabetes and obesity in C57BL/
6J and BALB/c is described in Table 2.
In vitro adipocyte differentiation from 3T3-L1 cells and
induction of IR
3T3-L1 fibroblasts were differentiated into adipocytes by a
protocol adapted from Nugent et al. [18]. 3T3-L1 fibroblasts
(LGC standard, Molsheim, France), between passages 4 and 8
were cultured in a growing medium containing DMEM (Life
technologies, Saint Aubin, France), 25 mmol/l glucose, 4 mmol/l
L-glutamine, 1 mmol/l sodium pyruvate, 10% FBS (PAA
laboratories, Velizy-Villacoublay, France), 1% penicillin/strepto-
mycin in humidified air at 37uC and 5% CO2. Two days after
confluence, cells were incubated in a differentiating medium
containing the growing medium supplemented with 0.25 mmol/l
dexamethasone, 500 mmol/l 3-isobutyl-1-methylxanthine (IBMX),
0.4 mmol/l insulin (Sigma Aldrich, Saint Quentin Fallavier,
France). After three days, cells were placed in differentiating
medium supplemented with 0.4 mmol/l insulin and at day7
mature adipocytes were obtained and maintained in differentiating
medium with 5% FBS. After differentiation, 3T3-L1 adipocytes
were weaned for two days in a low-glucose-medium (DMEM,
5.5 mmol/l glucose, L-glutamine, sodium pyruvate, 5% FBS).
Then, IR was induced in 3T3-L1 adipocytes within 48 h following
culture in a high-glucose/high-insulin-medium as described
previously [19,20]. IR was determined by glucose uptake assay.
3T3-L1 adipocytes were differentiated in 24-well plates and serum
starved for 4 h in DMEM. They were then washed with a pre-
warmed buffer containing PBS (Phosphate Buffered Saline),
0.5 mmol/l MgCl2, 0.9 mmol/l CaCl2, 0.2% BSA. Insulin
(100 nmol/l) stimulation was performed for 20 min. Cells were
then incubated with 3H-2-deoxy-glucose (18.5 kBq/well) for
10 min. Cells were solubilized and the radioactivity counted
Modulation of miR-125a expression in vitro in 3T3-L1
adipocytes
After differentiation 3T3-L1 adipocytes were transfected during
48 h with either the mature miriDIAN mimic mmu-miR-125a-5p,
cel-miR-67 as a transfection control, or 50 nmol/l mature
miriDIAN inhibitor (Thermo Scientific, Dharmacon, Saint
Leon-Rot, Germany) miR expression was assessed by q (quanti-
tative) RT-PCR. Mmu-miR-125a-5p mature sequence targeted by
miriDIAN inhibitor and corresponding to miriDIAN mimic is
UCCCUGAGACCCUUUAACCUGUGA, cel-miR-67 mature
sequence is UCACAACCUCCUAGAAAGAGUAGA. 3T3-L1
adipocytes were transfected in a total volume of 500 ml/well.
Dharmafect1 (0.25 ml/cm2, Thermo Scientific, Dharmacon, Saint
Leon-Rot, Germany) was used as a transfection reagent.
MiR and gene expression
Tissues and cells were homogenized in Qiazol (Qiagen,
Courtaboeuf, France). Total RNA was prepared as previously
described [6]. The fraction containing miRs was extracted with
miRNeasy mini kit (Qiagen, Courtaboeuf, France) and stored at2
80uC. RNA concentration was determined with Nanodrop
(Nanodrop ND-1000, Thermoscientific, Horsham, UK). QRT-
PCR was carried out using either TaqMan microRNA assay (hsa-
miR-125a-5p-002198, Life technologies, Saint Aubin, France) or
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SYBR Green expression assay (miScript reverse transcription kit,
miScript SYBR Green PCR Kit, miScript Primer Asssay
Mm_miR-125a_1-MS00001533, Rotor-Gene SYBR Green PCR
Kit, Qiagen, Courtaboeuf, France). MiR-16-MS00031493, U6-
MS00033740, (Qiagen, Courtaboeuf, France) and small nucleolar
RNA202-001232 (Life technologies, Saint Aubin, France) were
used as normalizing endogenous control for human tissues, cell
culture samples and mouse tissues, respectively. Oligonucleotide
sequences used are the following: Mouse Rtn2 (Reticulon 2) 59-
CTTTAGCATCGTGTCCGT (forward), 59-TGCAGCACTT-
TGCGGTAA (reverse); Mouse Tef (Thyrotroph embryonic factor) 59-
ATGGACCTGGATGAGTTC (forward), 59-GCAGACTCC-
TTTCCTTCAA (reverse); Mouse Ube2l3 (Ubiquitin-conjugating
enzyme E2L 3) 59-CCGCAAATGTGGAATGAA (forward), 59-
AGGAACAATAAGCCCTTG (reverse); Mouse Masp1 (Mannan-
binding lectin serine peptidase 1) 59-AAAGATGCTGTGCTGGT
(forward), 59-GAATAGACTCCATAGCGAT (reverse); Mouse b-
Actin 59-GACGATGCTCCCCGGGCTGTATTC (forward), 59-
TCTCTTGCTCTGGGCCTCGTCACC (reverse); Human Rtn2
59-AGCAGACGGAACGTTTGT (forward), 59-GAATCCAC-
GAGGTCTTCT (reverse); Human Tef 59-ATGGACCTGGAT-
GAGTTC (forward), 59-CAGACTCCTTCCCTTCTA (reverse);
Human Ube2l3 59-AGGAGGCTGATGAAGGAC (forward), 59-
TCGGTGGTTTGAATGGGTA (reverse); Human Masp1 59-
ACAACGACAACAGGACCT (forward), 59-GGTAAGGGTT-
TGGGAAGT (reverse); Human b-Actin 59-CTCTTCCAGC-
CTTCCTTCCT (forward), 59-AGCACTGTGTTGGCGTA-
CAG (reverse).
Genome-wide gene transcription profiling
Mice fat fed for 1 week (BALB/c) and 15 weeks (C57BL/6J) and
their respective age matched controls, which were used for miR-
125a expression analysis, were selected for gene transcription
profiling. RNA probes prepared from BALB/c mice were
hybridized to Affymetrix expression arrays 430 A and B
(Affymetrix UK ltd, High Wycombe, UK), containing 22,690
and 22,576 probesets, respectively, and allowing quantification of
the abundance of transcripts corresponding to 13,250 (chip A) and
7577 (chip B) independent gene and EST sequences. Probes
prepared from C57BL/6J mice were hybridized to Affymetrix
arrays U430 2.0, which were designed to contain all probesets of
arrays 430 A and B on a single chip. Experiments are MIAME
compliant and full protocols and data are publicly available (www.
ebi.ac.uk/arrayexpress/) under the accessions E-BAIR-12 (BALB/
c) and E-BAIR-9 (C57BL/6J). Affymetrix-based gene transcription
profiling was performed as previously described [6].
Pathway analysis of gene transcription data
Mouse transcriptomic data were analyzed by Gene Set
Enrichment Analysis (GSEA version 2.07, www.broad.mit.edu/
gsea) [21] using a gene set selected through the molecular
signature database (MSigDB C3-MIR; www.broadinstitute.org/
gsea/msigdb/collections.jsp#C3) for sharing 39UTR sequences
predicted to be targeted by miR-125a. Specific folders were
created for each array and GSEA was performed for each
transcriptome. Normalized enrichment score (ES) was calculated
for each gene set. It reflects the degree to which a gene set is over-
represented at the top or bottom of a ranked list of genes created
by GSEA for each gene set according to differential gene
expression between mice fed HFD or CHD. Positive and negative
ES indicated that the gene set was overexpressed or under-
expressed, respectively. For miR-125a associated gene set we
selected the leading edge subset which is the subset of members of
a gene set that contribute the most to the ES. A nominal p-value,
estimating the statistical significance of the ES for a single gene set,
was calculated after 1,000 permutations of the microarray samples
to correct for gene set size and multiple testing, and a false
discovery rate (FDR) was calculated. Gene set was considered
significantly enriched when its p-value was less than 0.05 and FDR
score was less than 0.25.
Statistical analyses
Statistics were performed with Prism (GraphPad, version 6.0).
Parametric student’s t-tests were performed to compare means
between two groups and ANOVA were performed to compare
means between more than two groups.
Processing and analysis of the Affymetrix CEL file data was
carried out using the BioConductor packages in the R language
and environment as previously reported [6]. Gene chip data were
normalised using RMA quantile normalization [22]. To correct
for multiple testing, we used the FDR of Benjamini & Hochberg
[23] to control the proportion of false positives at 5%.
Results
MiR-125a shows an opposite expression pattern in
sensitive and resistant strains in response to high fat diet
feeding
To test causal relationships between IR and miR-125a
expression, we used complementary ex vivo and in vitro experimen-
tal systems designed to modulate either insulin sensitivity or the
expression of this miR. We have characterized the short and long-
term consequences of fat feeding on the onset and progression of
diabetes and obesity in C57BL/6J and BALB/c (Table 2) [7],
which demonstrate contrasting pathophysiological patterns and
dynamics of adaptation to HFD feeding in the two strains. Ex vivo,
in adipose tissue of BALB/c mice fed HFD for 1 week, miR-125a
was significantly overexpressed when compared to CHD-fed mice
(p,0.05) (Fig. 1A). This effect was not replicated in this strain after
prolonged HFD feeding. In contrast, in C57BL/6J, miR-125a
expression was unchanged in fat in response to 1 week HFD
feeding but significantly overexpressed when the dietary stimulus
was applied for 15 weeks (Fig. 1B).
We then tested the effects of miR-125a expression modulation
on glucose transport in vitro in 3T3-L1 differentiated adipocytes
(Fig. 2). We initially used 3T3-L1 differentiated adipocytes
transfected with miR-125a inhibitor, which induced significant
down-regulation of the expression of the miR by over 11-fold
when compared to controls without inhibitor or with Cel-miR-67
(Fig. 2A). Our results showed that miR-125a inhibition had no
significant effects on glucose uptake both in the basal state (without
insulin) and after insulin stimulation (Fig. 2B).
MiR-125a was then overexpressed in 3T3-L1 adipocytes using a
specific miR mimic. We obtained a 14-fold stimulation of miR-
125a expression when transfected in the cells (Fig. 2C). Again in
this system, miR-125a overexpression had no significant effect on
glucose transport both in the basal state and after insulin
stimulation (Fig. 2D).
Finally, we measured miR-125a expression in response to
experimentally-induced IR in 3T3-L1 adipocytes (IR-3T3-L1)
obtained after culture in a medium supplemented with high
concentrations of glucose and insulin for 48 h (Fig. 1C–D). IR in
IR-3T3-L1 adipocytes was characterized by quantification of
insulin stimulated glucose uptake which was abolished in these
cells (Fig. 1C). We demonstrated that miR-125a expression level
was significantly decreased in these IR-3T3-L1 adipocytes when
compared to controls (p,0.01) (Fig. 1D). Collectively, these results
indicate that altered expression of miR-125a is secondary to IR ex
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vivo and in vitro rather than a cause of impairment of both glucose
transport and insulin sensitivity in vitro in 3T3-L1 adipocytes.
MiR-125a expression is downregulated in adipose tissue
of obese patients
To examine whether findings in rodent could be translated in
human context, we quantified miR-125a abundance by qRT-PCR
in biopsies of subcutaneous (Fig. 3A) and visceral (Fig. 3B) adipose
tissue from obese patients with and without diabetes and from
non-obese controls. We showed that miR-125a expression was
significantly down-regulated in both subcutaneous and visceral fat
of obese patients regardless of their diabetic status, when
compared to lean subjects. To further document possible
associations between miR-125a expression and intermediate
phenotypes collected in obese patients, we calculated correlations
between miR-125a levels and quantitative values of the pheno-
types (Fig. 3C, phenotypes in Table 1). Expression level of miR-
125a in subcutaneous adipose tissue negatively correlated with
total fat mass (r =20.50), serum leptin (r =20.44) and adipo-
nectin (p,0.05, r =20.58), and positively correlated with fat-free
mass (p = 0.05, r = 0.51) as well as with serum triglycerides (p,
0.05, r = 0.04) and cGT (p,0.05, r = 0.59).
These results provide confirmatory evidence that miR-125a
expression downregulation in adipose tissue is associated with
obesity and underline its possible association with intermediate
metabolic and hormonal phenotypes directly relevant to human
obesity.
Differential expression of miR-125a target genes is
enriched in HFD-fed mice
To test the effects of miR-125a on expression patterns of its
predicted transcript targets which can be further validated in
human obesity, we carried out genome-wide gene expression
studies in adipose tissue of mice previously used to demonstrate
miR-125a differential expression in response to acute (BALB/c) or
chronic (C57BL/6J) HFD feeding. Transcriptome data were
initially analyzed globally with GSEA (see methods for details)
using an inventory of groups of genes (gene sets) from the
Molecular Signature Database C3-MIR that contains genes
sharing a 39-UTR binding motif of miR-125a, which are therefore
likely transcript targets of the miR (Table S1). We identified a
significant enrichment of miR-125a specific gene sets in the
adipose tissue transcriptomes of C57BL/6J after 15 weeks of HFD
feeding (p,0.001, FDR=6.1024) and BALB/c after 1 week of
HFD feeding (p,0.02, FDR=0.04). MiR-125a gene sets were
overexpressed in both transcriptome datasets (ES=0.17 for
C57BL/6J and ES= 0.11 for BALB/c) (Fig. 4A). For each miR-
125a associated gene set we selected the leading edge subset in
order to retrieve the relevant transcriptome data (Fig. 4B and
Table S1). Analysis of leading edge subsets in the two
transcriptome datasets indicated that expression of 81 genes is
upregulated and that of 30 genes is downregulated in C57BL/6J.
Similar trends were found in BALB/c with 60 genes showing
upregulated expression and 46 genes showing downregulated
expression. Of note, GSEA highlighted largely different sets of
enriched genes in the two strains (Fig. 4B, Table S1), which may
result in different biological consequences.
Predominant overexpression of miR-125a targets in mice
showing upregulated expression of this miR is counter intuitive
with the general effect of miRs on gene transcription regulation
and suggests its indirect role on the regulation of HFD induced
transcription of the target gene set (Fig. 4A, B). We further
investigated miR-125a mRNA targets (Tef (Thyrotroph embryonic
factor), Masp1 (Mannan-binding lectin serine peptidase 1), Rtn2
Figure 1. Biological relationships between insulin resistance and miR-125a expression. MiR-125a expression levels were quantified by q
(quantitative) RT-PCR in adipose tissue of mice fed HFD for 1 week (A) or 15 weeks (B). The effect of in vitro insulin resistance (C) on miR-125a
expression (D) was tested by qRT-PCR in 3T3-L1 adipocytes. Expression of miR-125a was normalized with small nucleolar (sno) RNA202 in adipose
tissue and U6 in cultured cells. Data are expressed as mean6 SEM for 4–5 mice per group and for 3 replicated experiments in cultured cells. *p,0.05
significant differential expression of miR-125a between HFD-fed and control mice of the same strain. £££p,0.001 significant differences in glucose
transport stimulated by insulin in 3T3-L1 adipocytes. ‘‘p,0.01 significant differences in miR-125a expression between IR-3T3-L1 adipocytes and
control-3T3-L1 adipocytes.
doi:10.1371/journal.pone.0091375.g001
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(Reticulon 2), Ube2l3 (Ubiquitin-conjugating enzyme E2L3),
Adam9 (Disintegrin and metalloprotease 9)) significantly differen-
tially expressed in response to HFD feeding in the mouse
transcriptomes. Expression of these genes was upregulated in
response to HFD in C57BL/6J (Tef) or in BALB/c (Rtn2, Ube2l3).
On the other hand, we observed significant down-regulation of the
expression of the gene encoding Masp1 in BALB/c, which is
consistent with the expected transcriptional consequences of miR-
125a upregulated expression in this strain. Our results suggest
uncoupled regulations of the expression of miR-125a and its target
genes in adipose tissue of fat fed mice, which may underlie
pathological processes leading to obesity and IR.
To validate the coordinated regulation of the expression of miR-
125a and its target genes, we investigated the transcription level of
Tef, Masp1, Rtn2, Ube2l3 and Adam9 in IR-3T3-L1 adipocytes
(Fig. 4D). The expression of Tef, Masp1 and Rtn2 was consistently
significantly downregulated (p,0.05) in IR-3T3-L1 adipocytes
when compared to control adipocytes, which cannot be explained
by the downregulated expression of miR-125a in this experimental
system.
MiR-125a target genes are differentially expressed in
adipose tissue of obese patients
Mouse-to-human translational studies of miR function rely on
conservation of binding sites in target transcripts. We used Pictar
(http://pictar.mdc-berlin.de/), which is an algorithm designed to
identify microRNA targets based on 39 UTR alignments, to verify
that human Masp1, Rtn2, Tef and Ube2l3 also contain predicted
binding site for miR-125a (http://pictar.mdcberlin.de/cgibin/
PicTar_vertebrate.cgi?action = Search%20for%20targets%20of%
20a%20miRNA&name2=hsa-miR-125a).
To test transcriptional effects of miR-125a down-regulation in
human obesity, we quantified the expression of its target genes Tef,
Masp1, Rtn2, Ube2l3 and Adam9 in subcutaneous adipose tissue
samples of obese patients (Fig. 5A). Tef and Adam9 were not
differentially expressed between obese patients and non-obese
controls. In contrast transcript levels of Masp1 and Rtn2 were
significantly higher (p,0.05) in obese patients than in non-obese
controls, regardless of the diabetic status of the patients, which
may underlie a direct effect of miR-125a downregulated
expression. Transcript levels of Ube2l3 were significantly lower in
subcutaneous adipose tissue of both obese non diabetic (p,0.001)
and obese diabetic (p,0.01) patients which is inconsistent with the
expected consequence of downregulated expression of miR-125a
in obese patients, should Ube2l3 be considered as an indirect target
of this miR. In visceral adipose tissue, only Masp1 expression level
was significantly lower in obese non diabetic patients (p,0.05)
than in non-obese controls (Fig. 5B). These results underline the
incomplete concordance in expression patterns of miR-125a and
its transcript targets in human obesity, which may indicate that
these transcripts are indirect targets of miR-125a and may reflect
altered molecular adaptations in obesity potentially contributing to
disease pathophysiology.
Figure 2. MiR-125a modulation of expression in 3T3-L1 differentiated adipocytes do not affect adipocyte glucose uptake. The effects
of miR-125a expression downregulation (A) and upregulation (C) on glucose transport (B–D) were measured in vitro in 3T3-L1 differentiated
adipocytes. Expression of miR-125a was normalized with U6. Data are expressed as mean6 SEM for 3 replicated experiments. $$$p,0.001 significant
differences between miR-125a inhibitor/mimic, and control (not transfected cells) and cells transfected with C. elegans (Cel)-miR-67. £££p,0.001,
££p,0.01 significant differences in glucose transport stimulated by insulin in 3T3-L1 adipocytes.
doi:10.1371/journal.pone.0091375.g002
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Target genes of miR-125a show contrasting expression
patterns in adipose tissue of obese patients before and
after gastric bypass surgery
Gastric bypass in severely obese patients induces weight loss and
improved metabolic and inflammatory status [24]. We set out to
investigate expression of miR-125a targets in obese patients before
and after gastric bypass surgery. First, we analyzed the expression
profiles of predicted miR-125a transcript targets, identified in
GSEA leading edge subset, in obese patients before and after
gastric bypass (Fig. 6A and Table S1). Expression profile analysis
showed that 69 transcripts are downregulated and 39 transcripts
Figure 3. MiR-125a expression in adipose tissue of obese patients and correlations with physiological parameters. MiR-125a
expression was quantified by qRT-PCR in subcutaneous (A) and visceral adipose tissue (B) in obese patients (Ob) with or without diabetes (Diab) and
controls. MiR-125a expression level in obese patients was correlated with total triglycerides level, circulating leptin, c-glutamyltransferase (c-GT) and
adiponectin levels, fat mass and fat free mass percentages (C) in males (&) and females (N). Expression data were normalized with miR-16, an
endogenous miR whom expression level do not vary across group of study. Data are the mean 6 SEM of 6 non obese subjects for subcutaneous
adipose tissue, 7 non obese subjects for visceral adipose tissue, 9 obese non diabetic and 7 obese diabetic patients. Parametric Pearson correlation
tests were performed. *p,0.05, **p,0.01, ***p,0.001 significant differences between obese patients and controls.
doi:10.1371/journal.pone.0091375.g003
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are upregulated in obese patients when compared to non-obese
controls. After gastric bypass more transcripts are differentially
regulated in obese patients compared to control patients (80 are
upregulated and 81 are downregulated). More specifically Masp1,
Tef, Rtn2 and Ube2l3 showed contrasting expression patterns
before and after gastric bypass (Fig. 6B) but the effects were
statistically significant for Tef only, which highlights a possible
specific role of Tef in obesity and IR of obese patients. We found a
negative correlation between Tef expression level and fasting
insulinemia (p,0.05, r =20.58) and a positive correlation
between Tef expression level and QUICKI, (p,0.05, r = 0.59)
(Fig. 7). These findings further support the role of miR-125a and
its transcript targets in the adaptation of IR and obesity in
humans.
Discussion
We report reactive expression of miR-125a and its predicted
mRNA targets in adipose tissue from HFD-fed mice and obese
patients. Expression patterns of this miR varied in response to an
acute or chronic dietary stimulus in mice susceptible (C57BL/6J)
or resistant (BALB/c) to diet induced obesity, as well as in insulin
resistant adipocytes in vitro. Predicted transcript targets of the miR
showed altered expression through GSEA of genome-wide
transcriptome data in both C57BL/6J and BALB/c, but different
Figure 4. Expression patterns of miR-125a target gene sets in fat fed mice and in insulin resistant adipocytes. Gene set enrichment
profiles of miR-125a gene targets (A) were determined for BALB/c mice after 1 week of HFD feeding (left) and C57BL/6J mice after 15 weeks of HFD
feeding (right). Heatmap of miR-125a leading edge subsets are shown for fat fed C57BL/6J (top) and BALB/c (bottom) mice (B), alongwith enriched
target genes significantly differentially expressed in these mice (C). Expression of Tef,Masp1, Rtn2, Ube2l3 and Adam9 was quantified by qRT-PCR in IR-
3T3-L1 (&) and control (%) adipocytes (D). Expression level was normalized with mouse b-Actin. Data are the mean 6 SEM of 4 cultured cell
replicates. *p,0.05 significant differences between IR-3T3-L1 adipocytes and control-3T3-L1 adipocytes.
doi:10.1371/journal.pone.0091375.g004
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subsets of genes contributed to global gene set enrichment in the
two strains. Furthermore the expression level of miR-125a
transcript target Tef was associated with insulin resistance status
and Tef showed evidence of contrasting differential expression in
obese patients before and after gastric surgery, a situation known
to improve metabolic and inflammatory conditions. These results
provide functional links between expression of miR-125a and its
transcript targets in adipose tissue and IR and obesity.
MiR-125a shows a broad spectrum of functions, primarily
characterized in development and cell differentiation, apoptosis,
viral infection, carcinogenesis and autoimmune diseases [25,26].
The impact of miR-125a in obesity, T2DM and IR, as well as in
inflammation which is an important pathophysiological feature in
obesity [27] relevant to our study have recently emerged from
experimental studies in animal models and in humans. Abundance
of miR-125a is increased in insulin resistant diabetic GK rats [14],
as observed in fat fed mice in our study. Expression of miR-125a is
also increased in macrophages after induction of proinflammatory
response by oxidized LDL stimulation [28]. In humans, miR-125a
expression is enhanced during adipogenic differentiation of
Figure 5. MiR-125a target gene expression regulation in adipose tissue of obese patients. Expression of Tef, Masp1, Rtn2, Ube2l3 and
Adam9 was quantified by qRT-PCR in subcutaneous (A) and visceral (B) adipose tissue of obese patients (Ob) with diabetes (Diab) or without
(NonDiab) and non obese subjects (Controls). Expression levels were normalized with human b-Actin. $p,0.05, $$p,0.01, $$$p,0.001 significantly
different to non obese subjects.
doi:10.1371/journal.pone.0091375.g005
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multipotent stromal cells [29]. These observations support an
acute physiological reactivity of miR-125a expression in adipose
tissue of the genetically different mouse strains tested here, in a
situation where adipocyte formation and inflammatory processes
are stimulated by HFD-induced IR and obesity in mice showing
strong susceptibility (C57BL/6J) and relative resistance (BALB/c)
to these anomalies [7]. Conversely, downregulated expression of
miR-125a in obese ob/ob mice [30], as observed in obese patients
in our study, may underlie the existence of adaptative pathological
mechanisms contributing to obesity pathogenesis in obese
individuals.
A central issue in the possible involvement of miR-125a in IR
and obesity lies in the definition of causal relationships between its
abundance and phenotype alterations. We showed that modula-
tion of miR-125a expression in vitro in 3T3-L1 adipocytes does not
significantly affect glucose transport, whereas experimentally
induced IR is associated with reduced miR-125a abundance.
Our observations suggest that altered expression of miR-125a is
reactive to IR and concur with results in obese patients.
Correlations between miR-125a abundance and physiological
parameters of insulin sensitivity in obese patients also suggest that
changes in the expression of this miR reflect highly reactive
adaptation to metabolic and/or hormonal changes associated with
obesity, but may not play a direct causal role in the disease.
Changes in miR-125a expression may have indirect pathophys-
iological consequences mediated by its transcript targets.
Identification of molecular mechanisms that mediate functional
consequences of miR differential expression is a central issue in
miR biology. Target genes of miRs share DNA elements that allow
interactions between miRs and mRNAs, but the transcripts
regulated by a miR do not necessarily share any biological
function [31]. The definition of groups of transcripts regulated by
miRs can provide crucial information to understand the biological
endpoints of miR. However, it remains based on in silico prediction
of base pairing interactions that requires experimental validation,
for example through combined analysis of miR and gene
expression, which allows direct integration of miRs in functional
networks [32]. Parallel quantification of miR-125a and genome-
wide gene transcription in adipose tissue in the same mice allowed
analysis of coordinated expression of miR-125a and its predicted
mRNA targets in response to HFD feeding. Following GSEA, we
were able to establish a significant enrichment of miR-125a targets
Figure 6. Expression profile of miR-125a target gene in adipose tissue of obese patients before and after gastric bypass. Heatmaps of
miR-125a leading edge subsets are shown for obese patients before (top) or after gastric bypass (bottom) when compared to lean subjects (A).
Patterns of expression for Tef, Masp1, Rtn2, Ube2l3 and Adam9 in these groups are illustrated. Cells are hatched when differences are not statistically
significant (B).
doi:10.1371/journal.pone.0091375.g006
Figure 7. Tef expression level in subcutaneous adipose tissue is associated with fasting insulinemia and Quantitative insulin
sensitivity index (QUICKI) in obese patients. Correlations between Tef expression level (2-DCT unit) and fasting insulinemia (A) and QUICKI (B)
were calculated in male (&) and female (N) obese patients.
doi:10.1371/journal.pone.0091375.g007
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among differentially expressed genes in response to acute or
chronic HFD feeding in BALB/c and C57BL/6J, respectively,
thus providing experimental evidence that the genes encoding
these transcripts are, to a large extent, genuine targets of miR-
125a. These results also indicate that miR-125a expression
reactivity to HFD, obesity and/or IR should have significant
functional consequences in adipose tissue. Furthermore, tran-
scripts contributing to gene set enrichment largely differ in
C57BL/6J and BALB/c, which may account for metabolic and
hormonal divergences in their response to HFD feeding.
We focused further analyses on five differentially expressed
genes (Adam9, Masp1, Rtn2, Tef, Ube2l3) in the mouse transcrip-
tome datasets, which we selected for their differential expression
between HFD-fed and CHD-fed mice, their leading role in
enrichment of miR-125a gene targets, and their known role in the
regulation of body weight, insulin signaling or inflammation.
Adam9 is an insulin-like growth factor binding protein-5 protease
associated with adiponectin, which may modulate the develop-
ment of the metabolic syndrome [33]. Activation of Masp1 can
trigger local inflammation mediated by mannose-binding lectin
binding to damaged endothelial cells [34]. The protein Rtn2 plays
an important role in membrane translocation of GLUT4 [35] and
Ube2l3 interacts with the ubiquitin ligase WWP1, a positive
regulator of life span in response to dietary restriction in C. elegans
[36]. Finally, Tef contributes to the circadian transcription of genes
encoding acyl-CoA thioesterases leading to the release of fatty
acids [37].
Based on expression patterns of the selection of miR-125a
predicted targets, we did not find evidence of systematically
conserved effects of changes in miR-125a level on transcript
abundance in adipose tissue that may significantly contribute to
obesity and IR in fat fed mice and in humans. For example,
upregulated expression of Masp1 in obese patients could reflect
adipose tissue inflammation, whereas Adam9 overexpression may
underlie protective mechanisms against the metabolic syndrome.
Consistent down-regulated expression of Tef in adipose tissue in
C57BL/6J mice and in obese patients may underlie perturbations
leading to IR and deteriorated lipid and glucose metabolism.
Correlations between Tef transcript level, fasting insulinemia and
QUICKI in obese patients support this hypothesis. Furthermore
Tef showed contrasting expression patterns in obese patients before
and after gastric bypass which may be due to improved insulin
sensitivity, which occurs following gastric surgery [38].
An important challenge in miR studies in experimental systems
remains to dissect out direct and indirect effects of miRs on gene
expression and phenotypic endpoints. There is a general consensus
supporting a predominant effect of miRs on gene expression
silencing through various processes, even though examples of
transcription stimulation have been reported [39]. One would
therefore anticipate that expression of a miR and its mRNA
targets should systematically exhibit coordinated regulation.
However functional relationships between miR and mRNA are
far more complex and miR abundance and activity can be
regulated by the target mRNA it binds [31] These complex
mechanisms may explain the general lack of coordinated
regulation in the expression of miR-125a and its mRNA targets
in fat fed mice and in obese patients. Nevertheless, contrasting
expression of miR-125a and Masp1 in both fat fed mice and obese
individuals suggests that Masp1 is a direct target of this miR, which
mediates the effect of miR-125a on inflammation in the adipose
tissue.
Collectively, our findings based on investigations of coordinated
expression patterns of miR-125a and its mRNA targets in adipose
tissue and cell lines underline the role of miRs in the biology of
adipose tissue and contribute to improved knowledge of miR-125a
mediated molecular mechanisms, bridging its known function in
immunological processes [25] to novel molecular regulatory
mechanisms relevant to IR and obesity pathogenesis in mice and
humans. They suggest highly reactive expression of miR-125a in
experimentally-induced and spontaneous IR and obesity, which
may trigger molecular mechanisms associated with IR and
inflammation in adipose tissue. Tissue level of miR-125a and
some of its transcript targets may represent molecular markers of
obesity and IR, as well as recovery processes from obesity and IR.
Supporting Information
Table S1 Mouse miR-125a predicted target gene ex-
pression profile in mice and humans are listed in table
S1.
(XLSX)
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